Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: Diagnosis, predictive markers, treatment, and preventive measures

Peritoneal Dialysis International

Volumn 25, Issue SUPPL. 4, 2005, Pages

  Kawaguchi, Yoshindo ^a   Saito, Akira ^b   Kawanishi, Hideki ^c   Nakayama, Masaaki ^a   Miyazaki, Masanobu ^d   Nakamoto, Hidetomo ^e   Tranæus, Anders ^f  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TSUCHIYA GENERAL HOSPITAL   (Japan)

^d NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Department of Nephrology   (Japan)

^f Baxter Limited   (Japan)

Author keywords

Complications; Encapsulating peritoneal sclerosis; EPS; Management recommendations; SEP

Indexed keywords

ACETIC ACID; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CA 125 ANTIGEN; CHLORHEXIDINE; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; DECORIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHYLPREDNISOLONE; PLASTICIZER; PREDNISOLONE; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADENOVIRUS; CLINICAL FEATURE; DISEASE MARKER; HUMAN; INCIDENCE; JAPAN; KIDNEY DISEASE; MORTALITY; NONHUMAN; PERITONEAL BIOPSY; PERITONEAL DIALYSIS; PERITONEUM LAVAGE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCLEROSING PERITONITIS; SYMPTOMATOLOGY; TOTAL PARENTERAL NUTRITION; TREATMENT PLANNING; TREATMENT WITHDRAWAL; VIRAL GENE DELIVERY SYSTEM;

EID: 27744524289     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502504s12     Document Type: Review

References (83)

1. Kawaguchi Y, Ishizuka T, Imada A, Oohira S, Kuriyama S, Nakamoto H, et al. Searching for the reasons for drop-out from peritoneal dialysis: a nationwide survey in Japan. Perit Dial Int 2003; 23(Suppl 2):S175-7.
2. Imada A, Kawaguchi Y, Kumano K, Nomoto Y, for the CAPD-Related Peritonitis Study Group in Japan. A multicenter study of CAPD-related peritonitis in Japan (Japanese). J Jpn Soc Dial Ther 2001; 34:1157-62.
3. Nakai S, Shinzato T, Nagura Y, Masakane I, Kitaoka T, Shinoda T, et al. for the Patient Registration Committee, Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan (as of 31 December 2001). Ther Apher Dial 2004; 8:3-32.
4. Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawa K. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis 1996; 28:420-7.
5. Kawanishi H, for the Long-Term Peritoneal Dialysis Study Group. Encapsulating peritoneal sclerosis in Japan: prospective multicenter controlled study. Perit Dial Int 2001; 21(Suppl 3):S67-71.
6. Nakamoto H, Kawaguchi Y, Suzuki H. Encapsulating peritoneal sclerosis in patients undergoing continuous ambulatory peritoneal dialysis in Japan. Adv Perit Dial 2002; 18:119-23.
7. Kawanishi H, Kawaguchi Y. Prevalence and therapeutic outcome of sclerosing encapsulating peritonitis (EPS) - a multicenter study in Japan (Japanese). Jin To Toseki 2000; 49(Suppl):225-8.
8. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998; 13:154-9.
9. Oules R, Challah S, Brunner FP. Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant 1988; 3:66-9.
10. Rottembourg J, Issad B, Langlois P, Tranbaloc R, Adamou A, DeGroc F, et al. Loss of ultrafiltration and sclerosing encapsulating peritonitis during CAPD: evaluation of the potential risk factors. Adv CAPD 1985; 1:109-17.
11. Wilms H, Steinhauer HB, Riede UN, Kirste G. Sclerosing peritonitis following continuous ambulatory peritoneal dialysis (German). Chirurg 1986; 57:737-40.
12. Celicout B, Levard H, Hay J, Msika S, Fingerhut A, Pelissier E. Sclerosing encapsulating peritonitis: early and late results of surgical management in 32 cases. French Associations for Surgical Research. Dig Surg 1998; 15:697-702.
13. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20(Suppl 4):S43-55.
14. Nomoto Y, Kawaguchi Y, Sakai S, Hirano H, Kubo H, Ohira S. et al. Sclerosing encapsulating peritonitis (SEP) in patients on continuous ambulatory peritoneal dialysis - definition, diagnosis, and treatment recommendations, 1997 update (Japanese). J Jpn Soc Dial Ther 1998; 31: 303-11.
15. Kawanishi H, Harada Y, Noriyuki T, Kawai T, Takahashi S, Moriishi M, et al. Treatment options for encapsulating peritoneal sclerosis based on progressive stage. Adv Perit Dial 2001; 17:200-4.
16. Mactier RA. The spectrum of peritoneal fibrosing syndromes in peritoneal dialysis. Adv Perit Dial 2000; 16: 223-8.
17. Taylor PM. Image-guided peritoneal access and management of complications in peritoneal dialysis. Semin Dial 2002; 15:250-8.
18. Campbell S, Clarke P, Hawley C, Wigan M, Kerlin P, Butler J, et al. Sclerosing peritonitis: identification of diagnostic, clinical, and radiological features. Am J Kidney Dis 1994; 24:819-25.
19. Hollman AS, McMillan MA, Briggs JD, Junor BJ, Morley P. Ultrasound changes in sclerosing peritonitis following continuous ambulatory peritoneal dialysis. Clin Radiol 1991; 43:176-9.
20. Verbanck JJ, Schoonjans RS, Vandewiele IA, Segaert MF, Crolla DP, Tanghe WR. Sclerosing peritonitis with gross peritoneal calcification and abdominal wall abscess secondary to bowel perforation: ultrasonographic appearance. J Clin Ultrasound 1997; 25:136-40.
21. Hare CM. Radiological view of sclerosing peritonitis. Nephrol Dial Transplant 1999; 14:497-8.
22. Choi JH, Kim JH, Kim JJ, Jin SY, Choi DL. Large bowel obstruction caused by sclerosing peritonitis: contrast-enhanced CT findings. Br J Radiol 2004; 77:344-6.
23. Korzets A, Korzets Z, Peer G, Papo J, Stern D, Bernheim J, et al. Sclerosing peritonitis. Possible early diagnosis by computerized tomography of the abdomen. Am J Nephrol 1988; 8:143-6.
24. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al., for the Peritoneal Biopsy Study Group. Morphological changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
25. Ohsuki H, Ogawa H, Ono M, Saito A. Ultrasonographic evaluation of mesentery in CAPD patients. In: Ota K, Maher J, Winchester J, Hirszel P, eds. Current Concepts in Peritoneal Dialysis. Amsterdam: Excerpta Medica; 1992: 489-93.
26. Yamamoto T, Izumotani T, Otoshi T, Kim M. Morphological studies of mesothelial cells in CAPD effluent and their clinical significance. Am J Kidney Dis 1998; 32:946-52.
27. Nakayama M, Yamamoto H, Ikeda M, Hasegawa T, Kato N, Takahashi H, et al. Risk factors and preventive measures for encapsulating peritoneal sclerosis - Jikei experience 2002. Adv Perit Dial 2002; 18:144-8.
28. Kawanishi H, Kawaguchi Y. Prevalence and therapeutic outcome of sclerosing encapsulating peritonitis (EPS) - a multicenten study in Japan (Japanese). Jin To Toseki 2000; 49(Suppl):225-8.
29. Nakayama M, Ikeda M, Katoh N, Hayakawa H, Numata M, Otsuka Y, et al. Long-standing high-transport membrane as a risk factor for EPS development after PD withdrawal: an analysis based on changes in peritoneal function during and after CARD withdrawal (Japanese). Nippon Jinzo Gakkai Shi 2002; 44:396-401.
30. Moriishi M, Kawanishi H, Kawai T, Takahashi S, Hirai T, Shishida M, et al. Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis. Adv Perit Dial 2002; 18:149-53.
31. Keating JP, Neill M, Hill GL. Sclerosing encapsulating peritonitis after intraperitoneal use of povidone iodine. Aust N Z J Sung 1997; 67:742-4.
32. Mackow RC, Argy WP, Winchester JF, Rakowski TA, Fields PA, Rotellar C, et al. Sclerosing encapsulating peritoneal in rat induced by long-term intraperitoneal administration of antiseptics. J Lab Clin Med 1998; 112:363-71.
33. Mackow RC, Winchester JF, Argy WP, Andrew PM, Fields PA, Bates S, et al. Sclerosing encapsulating peritoneal in rats: an experimental study with intraperitoneal antiseptics. Contrib Nephrol 1987; 57:213-18.
34. Lo WK, Chan KT, Leung AC, Pang SW, Tse CY. Sclerosing peritonitis complicating continuous ambulatory peritoneal dialysis with the use of chlorhexidine in alcohol. Adv Perit Dial 1990; 6:79-84.
35. Wieczorowska-Tobis K, Polubinska A, Breborowicz A, Oreopoulos D. A comparison of the biocompatibility of phosphate-buffered saline and Dianeal 3.86% in the rat model of peritoneal dialysis. Adv Perit Dial 2001; 17:42-6.
36. Dasgupta M. Strategies for intervention in and prevention of biofilm-related infection in peritoneal dialysis patients. Adv Perit Dial 2003; 19:195-7.
37. Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucase exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12:1046-51.
38. Yamamoto R, Nakayama M, Hasegawa T, Miwako N, Yamamoto H, Yokoyami K, et al. High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment. Adv Perit Dial 2002; 18:131-4.
39. Hoshii S, Honda M, Itami N, Oh S, Matsumura C, Moriya S, et al. Sclerosing encapsulating peritonitis in pediatric peritoneal dialysis patients. Pediatr Nephrol 2000; 14: 275-9.
40. Krediet RT, Imholz AL, Struijk DG, Koomen GC, Ariaz L. Ultrafiltration failure in continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13(Suppl2):S59-66.
41. Heimbürger O, Waniewski J, Werynski A, Tranæus A, Lindholm B. Peritoneal transport in CAPD patients with permanent loss ultrafiltration capacity. Kidney Int 1990; 38:495-506.
42. Krediet RT. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 2001; 21:560-7.
43. Wang T, Chen C, Heimbürger O, Waniewski J, Bergström J, Lindholm B. Hyaluronan decreases peritoneal fluid absorption in peritoneal dialysis. J Am Soc Nephrol 1997; 8:1915-20.
44. Zweers MM, de Waart DR, Smit W, Struijk DG, Krediet RT. Growth factors VEGF and IGF-β1 in peritoneal dialysis. J Lab Clin Med 1999; 134:124-32.
45. Szeto CC, Wong TY, Lai KB, Chow KM, Li PK. The role of vascular endothelial growth factor in peritoneal hyperpermeability during CAPD-related peritonitis. Perit Dial Int 2002; 22:265-74.
46. Seo MJ, Oh SJ, Kim SI, Cho KW, Jo I, Schaub T, et al. High glucose dialysis solutions increase synthesis of vascular endothelial growth factors by peritoneal vascular endothelial cells. Perit Dial Int 2001; 21(Suppl 3):S35-40.
47. Pecoits-Filho R, Araujo MR, Lindholm B, Stenvinkel P, Abensur H, Romao JE, Jr, et al. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 2002; 17:1480-6.
48. Zemel D, Imholz AL, de Waart DR, Dinkla C, Struijk DG, Krediet RT. Appearance of tumor necrosis factor-α and soluble INF-receptors I and II in peritoneal effluent of CAPD. Kidney Int 1994; 46:1422-30.
49. Park MS, Lee HA, Chu WS, Yang DH, Hwang SD. Peritoneal accumulation of AGE and peritoneal membrane permeability. Perit Dial Int 2000; 20:452-60.
50. Lee EA, Oh,JH, Lee HA, Kim SI, Park EW, Park KB, et al. Structural and functional alterations of the peritoneum after prolonged exposure to dialysis solutions: role of aminoguanidine. Perit Dial Int 2001: 21:245-53.
51. Numata M, Nakayama M, Norfors L, Hoff CM, Holmes CJ, Hosoya T, et al. A single nucleotide polymorphism (SNP) in the RAGE-429 T/C genotype may be related to encapsulated peritoneal sclerosis (EPS) in Japanese peritoneal dialysis (PD) patients (Abstract). J Am Soc Nephrol 2003; 14:214A.
52. Wong TY, Szeto CC, Szeto CY, Lai KB, Chow KM, Li PK. Association of eNOS polymorphism with basal peritoneal membrane function in uremic patients. Am J Kidney Dis 2003; 42:781-6.
53. Lee HY, Kim BS, Choi HY, Park HC, Kang SW, Choi KH, et al. Sclerosing encapsulating peritonitis as a complication of long-term continuous ambulatory peritoneal dialysis in Korea. Nephrology (Carlton) 2003; 8(Suppl 2):S33-9.
54. Pollock CA. Bloody ascites in a patient after transfer from peritoneal dialysis to hemodialysis. Semin Dial 2003; 16: 406-10.
55. Jenkins SB, Leng BL, Shortland JR, Brown PW, Wilkie ME. Sclerosing encapsulating peritonitis: a case series from a single U.K. center during a 10-year period. Adv Perit Dial 2001; 17:191-5.
56. Hendriks PM, Ho-dac-Pannekeet MM, van Gulik TM, Struijk DG, Phoa SS, Sie L, et al. Peritoneal sclerosis in chronic peritoneal dialysis patients: analysis of clinical presentation, risk factors, and peritoneal transport kinetics. Perit Dial Int 1997; 17:136-43.
57. Kawanishi H, Harada Y, Sakikubo E, Moriishi M, Nagai T, Tsuchiya S. Surgical treatment for sclerosing encapsulating peritonitis. Adv Perit Dial 2000; 16:252-6.
58. Pollock CA. Diagnosis and management of encapsulating peritoneal sclerosis. Perit Dial Int 2001; 21(Suppl 3): S61-6.
59. Imai H, Nakamoto H, Fukushima R, Yamanouchi Y, Ishida Y, Suzuki H. Glucocorticoid protects against the development of encapsulating peritoneal sclerosis on peritoneal dialysis. Adv Perit Dial 2002; 18:124-30.
60. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004; 44:729-37.
61. Nakamoto H, Imai H, Ishida Y, Yamanouchi Y, Inoue T, Okada H, et al. New animal models for encapsulating peritoneal sclerosis - role of acidic solution. Perit Dial Int 2001; 21(Suppl 3):S349-53.
62. Fagugli RM, Selvi A, Quintaliani G, Bianchi M, Buoncristiani U. Immunosuppressive treatment for sclerosing peritonitis. Nephrol Dial Transplant 1999; 14:1343-5.
63. Mori Y, Matsuo S, Sutoh H, Toriyama T, Kawahara H, Hotta N. A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Am J Kidney Dis 1997; 30:275-8.
64. Junor BJ, McMillan MA. Immunosuppression in sclerosing peritonitis. Adv Perit Dial 1993; 9:187-9.
65. Evrenkaya TR, Atasoyu EM, Unver S, Basekim C, Baloglu H, Tulbek MY. Corticosteroid and tamoxifen therapy in sclerosing encapsulating peritonitis in a patient on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2004; 19:2423-4.
66. del Peso G, Bajo MA, Gil F, Aguilera A, Ros S, Costero O, et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial 2003; 19:32-5.
67. Allaria PM, Giangrande A, Gandini E, Pisoni IB. Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent? J Nephrol 1999; 12:395-7.
68. Hoff CM, Shockley TR. Peritoneal dialysis in the 21st century: the potential of gene therapy. J Am Soc Nephrol 2002; 13(Suppl 1):S117-24.
69. Margetts PJ, Gyorffy S, Kolb M, Yu L, Hoff CM, Holmes CJ, et al. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 2002; 13:721-8.
70. Oreopoulos DG, Tzamaloukas AH. Peritoneal dialysis in the next millennium. Adv Ren Replace Ther 2000; 7:338-46.
71. Ota K, Akiba T, Nakao T, Nakayama M, Maeba T, Park MS, et al. Peritoneal ultrafiltration and serum icodextrin concentration during dialysis with 7.5% icodextrin solution in Japanese patients. Perit Dial Int 2003; 23:356-61.
72. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338-44.
73. Cooker LA, Choo CG, Luneburg P, Lamela J, Holmes CJ. Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro. Adv Perit Dial 1999; 15:17-20.
74. Barré DE, Chen C, Cooker L, Moberly JB. Decreased in vitro formation of AGEs with Extraneal solution compared to dextrose-containing peritoneal dialysis solutions. Adv Perit Dial 1999; 15:12-16.
75. Lee JH, Reddy DK, Saran R, Moore HL, Twardowski ZJ, Nolph KDA, et al. Advanced glycosylation end-products in diabetic rats on peritoneal dialysis using various solutions. Perit Dial Int 2000; 20:643-51.
76. Bajo MA, Selgas R, Castro MA, del Peso G, Diaz C, Sanchez-Tomero JA, et al. Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo. Perit Dial Int 2000; 20:742-7.
77. Davies S, Brown E, Rutherford P, Meeus F, Borras M, Riegel W, et al. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int (In press).
78. Hoff CM. In vitro biocompatibility performance of Physioneal. Kidney Int 2003; 64(Suppl 88):S57-74.
79. ter Wee PM, Beelen RH, van den Born J. The application of animal models to study the biocompatibility of bicarbonate-buffered peritoneal dialysis solutions. Kidney Int 2003; 64(Suppl 88):S75-83.
80. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranæus A, et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney In 2001; 59: 1529-38.
81. Wilkie M, Plant M, Edwards L, Brown C. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival. Perit Dial Int 1997; 17:84-7.
82. Kuriyama S, Tomonari H. Corticosteroid therapy in encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2001; 16:1304-5.
83. Yamamoto H, Nakayama M, Yamamoto R, Otsuka Y, Takahashi H, Nato N, et al. Fifteen cases of encapsulating peritoneal sclerosis related to peritoneal dialysis: a single-center experience in Japan. Adv Perit Dial 2002; 18:135-8.